Biovail Corp. has reached a settlement, following a review by the Federal Trade Commission, with Anchen Pharmaceuticals LLP, Impax Laboratories, Inc., Watson Pharmaceuticals, Inc. and Teva Pharmaceutical Industries Ltd., related to Wellbutrin XL. Biovail had initiated patent-infringement litigation against companies that had filed aNDAs seeking approval to launch generic formulations of Wellbutrin XL, prior to the expiry of its patents. Terms of the settlement include: dismissal of Biovail&...